Suchergebnisse - "Receptors, Progesterone/metabolism"

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer: Capivasertib in hormone receptor-positive advanced breast cancer

Autoren: Turner, Nicholas C Oliveira, Mafalda Howell, Sacha J et al.

Quelle: Future Oncol
Turner, N C, Oliveira, M, Howell, S J, Dalenc, F, Cortés, J, Gomez, H L, Hu, X, Jhaveri, K, Krivorotko, P, Loibl, S, Murillo, S M, Park, Y H, Sohn, J-H, Toi, M, Tokunaga, E, Yousef, S, Zhukova, L, Bruin, E D, Grinsted, L, Schiavon, G, Foxley, A & Rugo, H S 2024, 'A plain language summary of the CAPItello-291 study : Capivasertib in hormone receptor-positive advanced breast cancer', Future oncology (London, England), vol. 20, no. 37, pp. 2901-2913. https://doi.org/10.1080/14796694.2024.2390791

Schlagwörter: Fulvestrant/administration & dosage, Receptors, Progesterone/metabolism, Receptor, ErbB-2, Clinical Studies as Topic, Receptor, ErbB-2/metabolism, Pyrimidines/therapeutic use, Breast Neoplasms, Middle Aged, Pyrimidines, Treatment Outcome, Breast Neoplasms/drug therapy, Receptors, Estrogen, Receptors, Plain Language Summary of Publication, Antineoplastic Combined Chemotherapy Protocols, Humans, ErbB-2/metabolism, Progesterone/metabolism, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Estrogen/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone, Fulvestrant, Receptor

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39283299

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial: patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Autoren: Oliveira, Mafalda Rugo, Hope S Howell, Sacha J et al.

Quelle: CAPItello-291 Study Group, Oliveira, M, Rugo, H S, Howell, S J, Dalenc, F, Cortes, J, Gomez, H L, Hu, X, Toi, M, Jhaveri, K, Krivorotko, P, Loibl, S, Morales Murillo, S, Okera, M, Nowecki, Z, Park, Y H, Sohn, J H, Tokunaga, E, Yousef, S, Zhukova, L, Fulford, M, Andrews, H, Wadsworth, I, D'Cruz, C & Turner, N C 2024, 'Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291) : patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial', The Lancet. Oncology, vol. 25, no. 9, pp. 1231-1244. https://doi.org/10.1016/S1470-2045(24)00373-5

Schlagwörter: Adult, Pyrrolidines, Receptors, Progesterone/metabolism, Receptor, ErbB-2, Receptor, ErbB-2/metabolism, Breast Neoplasms, Breast Neoplasms/drug therapy, Double-Blind Method, Receptors, Antineoplastic Combined Chemotherapy Protocols, Humans, Pyrroles, Patient Reported Outcome Measures, Pyrimidines/administration & dosage, Fulvestrant/therapeutic use, Fulvestrant, Aged, Middle Aged, Pyrrolidines/administration & dosage, Progression-Free Survival, Pyrimidines, Receptors, Estrogen, Quality of Life, ErbB-2/metabolism, Progesterone/metabolism, Female, Estrogen/metabolism, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Receptors, Estrogen/metabolism, Receptors, Progesterone, Receptor

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39214106
https://research.manchester.ac.uk/en/publications/a50132f2-a6b1-4556-8637-e8f10ea2799f
https://doi.org/10.1016/S1470-2045(24)00373-5
http://www.scopus.com/inward/record.url?scp=85202486021&partnerID=8YFLogxK
https://research.manchester.ac.uk/en/publications/a50132f2-a6b1-4556-8637-e8f10ea2799f
https://doi.org/10.1016/S1470-2045(24)00373-5

Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer

Autoren: Klein, Evelyn Kiechle, Marion Josipovic, Adriana et al.

Quelle: Breast Cancer Res Treat

Schlagwörter: Adult, 0301 basic medicine, Receptor, ErbB-2, Research, Breast Neoplasms, Middle Aged, Breast cancer, Prognostic biomarker, Predictive biomarker, EndoPredict, Adjuvant chemotherapy, Risk stratification, Prognosis, Risk Assessment, Disease-Free Survival, ddc, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Receptors, Estrogen, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, Prospective Studies, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Neoplasm Recurrence, Local/pathology [MeSH], Neoplasm Staging [MeSH], Risk Assessment/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Prospective Studies [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Biomarkers, Tumor/metabolism [MeSH], Disease-Free Survival [MeSH], Prognosis [MeSH], Neoplasm Recurrence, Local, Receptors, Progesterone, Aged, Neoplasm Staging

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38722442
https://repository.publisso.de/resource/frl:6521231
https://mediatum.ub.tum.de/1770720

Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses’ Health Studies

Autoren: Renée T. Fortner Kristen D. Brantley Shelley S. Tworoger et al.

Quelle: Breast Cancer Res Treat

Schlagwörter: Adult, Epidemiology, Nurses, Breast Neoplasms, Middle Aged, Breast Neoplasms/etiology [MeSH], Female [MeSH], Postmenopause [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Premenopause [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Breast cancer, Middle Aged [MeSH], Risk Factors [MeSH], Breast Neoplasms/epidemiology [MeSH], Recreation [MeSH], Risk, Menopause [MeSH], Proportional Hazards Models [MeSH], Menopausal status, Physical activity, Hormone receptor status, Nurses/statistics, Exercise [MeSH], Postmenopause, 03 medical and health sciences, 0302 clinical medicine, Receptors, Estrogen, Premenopause, Risk Factors, Humans, Recreation, Female, Menopause, Receptors, Progesterone, Exercise, Proportional Hazards Models

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38592542
https://repository.publisso.de/resource/frl:6504517

PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study

Autoren: Ballé, Judith Katharina Vetter, Martina Kenea, Tariku Wakuma et al.

Quelle: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

Schlagwörter: Adult, Rural Population, Survival, Receptor, ErbB-2, Breast Neoplasms, Ethiopia, Aged [MeSH], Intrinsic subtypes, Receptor, ErbB-2/metabolism [MeSH], Ethiopia/epidemiology [MeSH], Breast Neoplasms/therapy [MeSH], PAM50, Africa, Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Prospective Studies [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Breast Cancer, Rural Population [MeSH], Immunohistochemistry [MeSH], Biomarkers, Tumor/metabolism [MeSH], Research, Prognosis [MeSH], Gene Expression Profiling [MeSH], Biomarkers, Tumor, Humans, Prospective Studies, RC254-282, Aged, ddc:610, Gene Expression Profiling, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Prognosis, Immunohistochemistry, Receptors, Estrogen, Chemotherapy, Adjuvant, Female, Receptors, Progesterone

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39256703
https://doaj.org/article/d1d8fe71a42b4c2c90d5d660b7d42f77
https://repository.publisso.de/resource/frl:6490436

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia

Autoren: Dora Čerina Pavlinović Natalija Dedić Plavetić Ingrid Belac Lovasić et al.

Quelle: Breast J
The Breast Journal, Vol 2024 (2024)

Schlagwörter: Breast Neoplasms / drug therapy, Receptor, ErbB-2, receptor, receptors, Receptor, ErbB-2 / metabolism, chemotherapy, Class I Phosphatidylinositol 3-Kinases / genetics, ErbB-2, 0302 clinical medicine, breast neoplasms, estrogen, antineoplastic agents, RC254-282, Breast Neoplasms / mortality, breast tumor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Receptors, Estrogen / metabolism, Breast Neoplasms / therapy, Receptors, Progesterone / metabolism, Receptors, Estrogen, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal / therapeutic use, Breast Neoplasms / pathology, Female, PIK3CA mutations, Public aspects of medicine, RA1-1270, Receptors, Progesterone, Research Article, Adult, tumor, disease-free survival, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases, Croatia, Neoplasm Recurrence, Local / genetics, Breast Neoplasms, progesterone, Disease-Free Survival, 03 medical and health sciences, adjuvant, local, Biomarkers, Tumor, Humans, Retrospective Studies, Aged, Receptor, ErbB-2 / genetics, biomarkers, neoplasm recurrence, hormonal, Biomarkers, Tumor / genetics, Breast Neoplasms / genetics, Mutation, mutation, Neoplasm Recurrence, Local

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39742376
https://doaj.org/article/58fd4feb40884d6bb8fd7ad6d6f40a50
https://onlinelibrary.wiley.com/doi/10.1155/2024/5648845
https://doi.org/10.1155/2024/5648845
https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e12512
https://doi.org/10.1200/JCO.2024.42.16_suppl.e12512
https://urn.nsk.hr/urn:nbn:hr:105:788167
https://doi.org/10.1155/2024/5648845

On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer

Autoren: Bruno Valentin Sinn Katharina Sychra Michael Untch et al.

Quelle: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)

Schlagwörter: Adult, Neoplasm, Residual, Receptor, ErbB-2, Biopsy, Breast Neoplasms, Disease-Free Survival, Breast cancer, Lymphocytes, Tumor-Infiltrating, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, TILs, RC254-282, Aged, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Serial biopsies, Middle Aged, Prognosis, Neoadjuvant Therapy, Ki-67 Antigen, Treatment Outcome, Receptors, Estrogen, Chemotherapy, Adjuvant, Neoadjuvant therapy, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Neoadjuvant Therapy/methods [MeSH], Ki-67 Antigen/metabolism [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Biopsy [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Lymphocytes, Tumor-Infiltrating/metabolism [MeSH], Neoplasm, Residual/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Lymphocytes, Tumor-Infiltrating/immunology [MeSH], Biomarkers, Tumor/metabolism [MeSH], Disease-Free Survival [MeSH], Prognosis [MeSH], Ki-67, Female, Receptors, Progesterone

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39317942
https://doaj.org/article/7254adee1eef456f91cca8c6f84490e2
https://repository.publisso.de/resource/frl:6503837

Vaginal leiomyoma in a goat expressing the nuclear progesterone receptor (PGR): a case report

Autoren: Trzebiatowski, Lukas Kowalewski, Mariusz P Schmid, Sarah et al.

Weitere Verfasser: Trzebiatowski, Lukas Kowalewski, Mariusz P Schmid, Sarah et al.

Quelle: BMC Vet Res
BMC Veterinary Research, Vol 20, Iss 1, Pp 1-5 (2024)

Schlagwörter: 0301 basic medicine, Vaginal discharge, Vaginal Neoplasms, Goat Diseases, Leiomyoma, 10077 Institute of Veterinary Anatomy, Veterinary medicine, Goats, Sex steroid hormone, Case Report, 04 agricultural and veterinary sciences, 3. Good health, 0403 veterinary science, 03 medical and health sciences, Female [MeSH], Receptors, Progesterone/metabolism [MeSH], Goat Diseases/pathology [MeSH], Animals [MeSH], Leiomyoma/pathology [MeSH], Goat, Vaginal Neoplasms/veterinary [MeSH], Goats [MeSH], Leiomyoma/surgery [MeSH], Leiomyoma/veterinary [MeSH], Vaginal Neoplasms/pathology [MeSH], Reproductive disorder, Vaginal tumor, SF600-1100, 570 Life sciences, biology, Animals, Female, Receptors, Progesterone

Dateibeschreibung: ZORA_s12917_024_04035_6.pdf - application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38715073
https://doaj.org/article/916b7485493f43c69c7b4d75377549e4
https://repository.publisso.de/resource/frl:6508783
https://www.zora.uzh.ch/id/eprint/274906/
https://doi.org/10.5167/uzh-274906

Incorporating progesterone receptor expression into the PREDICT breast prognostic model

Autoren: Grootes, Isabelle Keeman, Renske Blows, Fiona M et al.

Weitere Verfasser: Grootes, Isabelle Keeman, Renske Blows, Fiona M et al.

Quelle: Eur J Cancer
ABCTB Investigators & kConFab Investigators 2022, ' Incorporating progesterone receptor expression into the PREDICT breast prognostic model ', European Journal of Cancer, vol. 173, pp. 178-193 . https://doi.org/10.1016/j.ejca.2022.06.011
2022, ' Incorporating progesterone receptor expression into the PREDICT breast prognostic model ', European journal of cancer (Oxford, England : 1990), vol. 173, pp. 178-193 . https://doi.org/10.1016/j.ejca.2022.06.011
ABCTB Investigators 2022, 'Incorporating progesterone receptor expression into the PREDICT breast prognostic model', European journal of cancer (Oxford, England : 1990), vol. 173, pp. 178-193. https://doi.org/10.1016/j.ejca.2022.06.011

Schlagwörter: Cancer Research, Breast Neoplasms/pathology, Receptors, Progesterone/metabolism, Receptor, ErbB-2, Receptor, ErbB-2/metabolism, THERAPY, Progesterone receptor, ErbB-2, Breast cancer, 0302 clinical medicine, Global Cancer Incidence and Mortality Patterns, Receptors, Estrogen receptor, 10. No inequality, Internal medicine, Progesterone, Original Research, Cancer, 2. Zero hunger, Manchester Cancer Research Centre, Cohort, Life Sciences, PREDICT Breast, Prognosis, 3. Good health, Oncology, Public Health and Health Services, kConFab Investigators, Medicine, Female, Cancers, Receptors, Progesterone, Life Sciences & Biomedicine, Receptor, Receptor, erbB-2, ADJUVANT TAMOXIFEN, Hazard ratio, Oncology and Carcinogenesis, ABCTB Investigators, Breast Neoplasms, R Medicine, Proportional hazards model, 1117 Public Health and Health Services, 03 medical and health sciences, breast cancer, SDG 3 - Good Health and Well-being, 3211 Oncology and carcinogenesis, Biochemistry, Genetics and Molecular Biology, Breast Cancer, Health Sciences, Humans, 1112 Oncology and Carcinogenesis, CANCER PATIENTS, Oncology & Carcinogenesis, erbB-2, Science & Technology, Confidence interval, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, Impact of Obesity on Cancer Risk and Prognosis, ESTROGEN-RECEPTOR, Gynecology, Prognostic Markers, Molecular Research on Breast Cancer

Dateibeschreibung: application/pdf; application/octet-stream; text; spreadsheet

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35933885
http://hdl.handle.net/10852/101859
https://doi.org/10.1016/j.ejca.2022.06.011
https://hdl.handle.net/1887/3563763
http://hdl.handle.net/10138/351520
https://curis.ku.dk/ws/files/327946679/Incorporating_progesterone_receptor.pdf
https://hdl.handle.net/20.500.11820/a7b70985-2ea0-4c9b-a077-242db8ae8492
https://www.pure.ed.ac.uk/ws/files/290256219/Incorporating_progesterone_receptor_expression_into_the_PREDICT_breast_prognostic_model.pdf
https://pure.manchester.ac.uk/ws/files/224514866/PIIS0959804922003628.pdf
https://doi.org/10.1016/j.ejca.2022.06.011
https://research.manchester.ac.uk/en/publications/e747df14-6ead-4597-b1a4-1210a8caddf0
https://escholarship.org/uc/item/9s51647n
https://eprints.soton.ac.uk/468307/

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903): The PARAGON trial (ANZGOG 0903)

Autoren: Edmondson, R J O'Connell, R L Banerjee, S et al.

Weitere Verfasser: Edmondson, R J O'Connell, R L Banerjee, S et al.

Quelle: PARAGON investigators 2021, 'Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus : The PARAGON trial (ANZGOG 0903)', Gynecologic Oncology, vol. 163, no. 3, pp. 524-530. https://doi.org/10.1016/j.ygyno.2021.09.010

Schlagwörter: Adult, Leiomyosarcoma, 0301 basic medicine, Carcinosarcoma/drug therapy, Receptors, Progesterone/metabolism, Sustainable Development Goals, Anastrozole, uterine carcinosarcoma, uterine leiomyosarcoma, 03 medical and health sciences, 0302 clinical medicine, Carcinosarcoma, Uterine Neoplasms/drug therapy, Uterine leiomyosarcoma, Receptors, 80 and over, Humans, Prospective Studies, Neoplasm Metastasis, SDG 3, Aged, Aged, 80 and over, Manchester Cancer Research Centre, Uterine carcinosarcoma, Aromatase Inhibitors, Leiomyosarcoma/drug therapy, Anastrozole/adverse effects, Aromatase inhibitor, Middle Aged, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, 3. Good health, Receptors, Estrogen, aromatase inhibitor, Uterine Neoplasms, Quality of Life, Progesterone/metabolism, Female, Aromatase Inhibitors/adverse effects, Estrogen/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/34625284
https://research.manchester.ac.uk/en/publications/a4447fca-4b40-4043-bd44-5f411c01edde
https://doi.org/10.1016/j.ygyno.2021.09.010
https://chesterrep.openrepository.com/handle/10034/626171
https://www.sciencedirect.com/science/article/pii/S0090825821013792
https://pubmed.ncbi.nlm.nih.gov/34625284/
https://www.gynecologiconcology-online.net/article/S0090-8258(21)01379-2/fulltext

Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study

Autoren: Somayeh Khazaei Ana Bosch Karin Jirström et al.

Quelle: Carcinogenesis
Godina, C, Khazaei, S, Tryggvadottir, H, Visse, E, Nodin, B, Jirström, K, Borgquist, S, Bosch, A, Isaksson, K & Jernström, H 2021, 'Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study', Carcinogenesis, vol. 42, no. 11, pp. 1314-1325. https://doi.org/10.1093/carcin/bgab090

Schlagwörter: RNA, Messenger/genetics, DOWN-REGULATION, Receptors, Progesterone/metabolism, Datasets as Topic, ALCOHOL, Breast Neoplasms, THERAPY, 03 medical and health sciences, 0302 clinical medicine, FACTOR-I RECEPTOR, Humans, Prospective Studies, RNA, Messenger, Cancer Biomarkers and Molecular Epidemiology, GENE-EXPRESSION, Insulin-Like Growth Factor Binding Proteins/genetics, Aged, Middle Aged, Prognosis, 3. Good health, Insulin-Like Growth Factor Binding Proteins, ESTROGEN-RECEPTOR, Receptors, Estrogen, Breast Neoplasms/metabolism, ENDOCRINE TREATMENT, Female, Receptors, Estrogen/metabolism, Receptors, Progesterone, RESISTANCE

Dateibeschreibung: application/pdf

Zugangs-URL: https://academic.oup.com/carcin/article-pdf/42/11/1314/41138082/bgab090.pdf
https://pubmed.ncbi.nlm.nih.gov/34606580
https://academic.oup.com/carcin/article/42/11/1314/6380882
https://pure.au.dk/ws/files/274258204/bgab090.pdf
https://pure.au.dk/ws/files/274258204/bgab090.pdf
https://pure.au.dk/portal/en/publications/0d285037-b48c-42f4-a54c-53bf2bc87cb6
https://doi.org/10.1093/carcin/bgab090
http://www.scopus.com/inward/record.url?scp=85121109873&partnerID=8YFLogxK

Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma

Autoren: Anne Tardivon Anne Vincent-Salomon Caroline Saint-Martin et al.

Weitere Verfasser: Anne Tardivon Anne Vincent-Salomon Caroline Saint-Martin et al.

Quelle: Modern pathology, Vol. 33, No 11 (2020) pp. 2198-2207

Schlagwörter: Receptor, ErbB-2, [SDV]Life Sciences [q-bio], Carcinoma, Lobular / immunology, Breast Neoplasms, ddc:616.07, 616.07, Receptor, ErbB-2 / metabolism, Breast Neoplasms / metabolism, Breast Neoplasms / immunology, Carcinoma, Lobular / mortality, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, 0302 clinical medicine, Lymphocytes, Tumor-Infiltrating / immunology, Humans, Carcinoma, Lobular / metabolism, Retrospective Studies, Breast Neoplasms / mortality, Carcinoma, Lobular / pathology, Age Factors, Middle Aged, Prognosis, Receptors, Estrogen / metabolism, 3. Good health, [SDV] Life Sciences [q-bio], Survival Rate, Carcinoma, Lobular, Receptors, Progesterone / metabolism, Receptors, Estrogen, Breast Neoplasms / pathology, Female, Receptors, Progesterone, Lymphocytes, Tumor-Infiltrating / pathology

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/32404955
https://hal.archives-ouvertes.fr/hal-03032297
https://www.nature.com/articles/s41379-020-0561-9.pdf
https://www.ncbi.nlm.nih.gov/pubmed/32404955
https://archive-ouverte.unige.ch/unige:155787
https://www.nature.com/articles/s41379-020-0561-9
https://pubmed.ncbi.nlm.nih.gov/32404955/
https://archive-ouverte.unige.ch/unige:155787

Zinc distribution within breast cancer tissue of different intrinsic subtypes

Autoren: Peter Rusch Alfred V. Hirner Oliver Schmitz et al.

Quelle: Arch Gynecol Obstet

Schlagwörter: Adult, 2. Zero hunger, 0301 basic medicine, 0303 health sciences, Receptor, ErbB-2, Chemie, Medizin, Breast Neoplasms, Pilot Projects, Gynecologic Oncology, Middle Aged, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Breast cancer, Receptors, Progesterone/analysis [MeSH], Germany/epidemiology [MeSH], Feasibility Studies [MeSH], Receptor, ErbB-2/analysis [MeSH], Biomarker, Zinc, Zinc/metabolism [MeSH], Zinc/analysis [MeSH], Biomarkers, Tumor/analysis [MeSH], Steroid receptor, Breast Neoplasms/pathology [MeSH], Laser Therapy [MeSH], Female [MeSH], Human epidermal growth factor receptor 2, Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Breast Neoplasms/chemistry [MeSH], Middle Aged [MeSH], Zinc/chemistry [MeSH], Laser ablation inductively coupled mass spectrometry (LA-ICPMS), Biomarkers, Tumor/metabolism [MeSH], Pilot Projects [MeSH], Mass Spectrometry/methods [MeSH], Receptors, Estrogen/analysis [MeSH], Mass Spectrometry, 3. Good health, 03 medical and health sciences, Receptors, Estrogen, Germany, Biomarkers, Tumor, Feasibility Studies, Humans, Female, Laser Therapy, Receptors, Progesterone, Aged

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00404-020-05789-8.pdf
https://pubmed.ncbi.nlm.nih.gov/32930875
https://pubmed.ncbi.nlm.nih.gov/32930875/
https://europepmc.org/article/MED/32930875
https://link.springer.com/content/pdf/10.1007/s00404-020-05789-8.pdf
https://link.springer.com/article/10.1007/s00404-020-05789-8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854450
https://www.ncbi.nlm.nih.gov/pubmed/32930875
https://repository.publisso.de/resource/frl:6466708
https://www.ncbi.nlm.nih.gov/pubmed/32930875
https://doi.org/10.1007/s00404-020-05789-8
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85090995657

Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study

Autoren: S. Krajnak C. Schnatz K. Almstedt et al.

Weitere Verfasser: S. Krajnak C. Schnatz K. Almstedt et al.

Quelle: Breast Cancer Res Treat

Schlagwörter: Adult, Aged, 80 and over [MeSH], Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Progression-Free Survival [MeSH], Antineoplastic Agents/administration, Breast Neoplasms/therapy [MeSH], Neoadjuvant Therapy/methods [MeSH], Administration, Oral [MeSH], Cyclophosphamide/administration, Case-Control Studies [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Dose-Response Relationship, Drug [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Clinical Trial, Retrospective Studies [MeSH], Middle Aged [MeSH], Administration, Metronomic [MeSH], Oncology, Methotrexate/administration, Mastectomy [MeSH], Receptor, ErbB-2, 610 Medizin, Administration, Oral, Antineoplastic Agents, Breast Neoplasms, Kaplan-Meier Estimate, 03 medical and health sciences, 0302 clinical medicine, 610 Medical sciences, Humans, Cyclophosphamide, Mastectomy, Aged, Aged, 80 and over, ddc:610, Dose-Response Relationship, Drug, Middle Aged, Neoadjuvant Therapy, Progression-Free Survival, 3. Good health, Methotrexate, Chemotherapy, Adjuvant, Case-Control Studies, Administration, Metronomic, Female

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s10549-020-05711-5.pdf
https://pubmed.ncbi.nlm.nih.gov/32495001
https://link.springer.com/content/pdf/10.1007/s10549-020-05711-5.pdf
https://pubmed.ncbi.nlm.nih.gov/32495001/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297707
https://link.springer.com/article/10.1007/s10549-020-05711-5
https://europepmc.org/article/PMC/PMC7297707
https://repository.publisso.de/resource/frl:6470722

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Autoren: K. Almstedt S. Mendoza M. Otto et al.

Weitere Verfasser: K. Almstedt S. Mendoza M. Otto et al.

Quelle: Breast Cancer Res Treat

Schlagwörter: Adult, Surveys and Questionnaires [MeSH], Clinical Decision-Making [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Risk Assessment [MeSH], Carcinoma, Lobular/metabolism [MeSH], Receptor, ErbB-2/metabolism [MeSH], Prognosis, Decision Support Techniques [MeSH], Endocrine therapy, Gene expression, Breast Neoplasms/pathology [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Humans [MeSH], Clinical Trial, Breast Neoplasms/genetics [MeSH], Retrospective Studies [MeSH], Carcinoma, Lobular/genetics [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Neoplasm Invasiveness [MeSH], Early breast cancer, EndoPredict, Treatment decision, Biomarkers, Tumor/genetics [MeSH], Prognosis [MeSH], Gene Expression Profiling [MeSH], Carcinoma, Lobular/pathology [MeSH], Receptor, ErbB-2, Clinical Decision-Making, 610 Medizin, Breast Neoplasms, Risk Assessment, Decision Support Techniques, 03 medical and health sciences, 0302 clinical medicine, 610 Medical sciences, Biomarkers, Tumor, Humans, Neoplasm Invasiveness, Aged, Retrospective Studies, Aged, 80 and over, ddc:610, Gene Expression Profiling, Middle Aged, 3. Good health, Carcinoma, Lobular, Receptors, Estrogen, Female, Receptors, Progesterone, Follow-Up Studies

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s10549-020-05688-1.pdf
https://pubmed.ncbi.nlm.nih.gov/32436145
https://link.springer.com/article/10.1007/s10549-020-05688-1
https://pubmed.ncbi.nlm.nih.gov/32436145/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275019
https://link.springer.com/content/pdf/10.1007/s10549-020-05688-1.pdf
https://repository.publisso.de/resource/frl:6470718

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study: a Dutch population-based study

Autoren: Simons, J.M. Koppert, L.B. Luiten, E.J. et al.

Weitere Verfasser: Simons, J.M. Koppert, L.B. Luiten, E.J. et al.

Quelle: Breast Cancer Res Treat
Breast Cancer Research and Treatment, 180, 3, pp. 725-733

Schlagwörter: Cancer Research, Receptors, Progesterone/metabolism, Receptor, ErbB-2, SEED LOCALIZATION, Receptor, ErbB-2/metabolism, MULTICENTER, UT-Hybrid-D, THERAPY, Breast cancer, 0302 clinical medicine, Sentinel lymph node biopsy, Axillary lymph node dissection, Antineoplastic Combined Chemotherapy Protocols, 10. No inequality, DISSECTION, Mastectomy, Netherlands, Aged, 80 and over, 2. Zero hunger, Carcinoma, Ductal, Breast, CHEMOTHERAPY, Middle Aged, Prognosis, Clinical Trial, Combined Modality Therapy, Neoadjuvant Therapy, Node positive, 3. Good health, Survival Rate, Oncology, Axillary staging, LYMPH-NODE BIOPSY, Marked node, IBCSG 23-01, Female, Receptors, Estrogen/metabolism, SENTINEL-NODE, Surgery - Radboud University Medical Center, NEGATIVE PATIENTS, Adult, Adolescent, Sentinel Lymph Node Biopsy/statistics & numerical data, Netherlands/epidemiology, Breast Neoplasms, Carcinoma, Lobular/drug therapy, Young Adult, 03 medical and health sciences, Breast Neoplasms/drug therapy, SDG 3 - Good Health and Well-being, Journal Article, Humans, RECURRENCE, Aged, Neoadjuvant Therapy/methods, Radboudumc 14: Tumours of the digestive tract RIHS: Radboud Institute for Health Sciences, Mastectomy/statistics & numerical data, Carcinoma, Lobular, Carcinoma, Ductal, Breast/drug therapy, Withholding Treatment, Axilla, Lymph Node Excision, Lymph Node Excision/statistics & numerical data, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s10549-020-05589-3.pdf
https://pubmed.ncbi.nlm.nih.gov/32180074
https://pure.eur.nl/en/publications/1d50bfc0-507f-4984-9dfc-7b7eeeb8bcbc
https://doi.org/10.1007/s10549-020-05589-3
https://research.utwente.nl/en/publications/46f9e155-42b4-469c-8a3a-39a6a2536034
https://doi.org/10.1007/s10549-020-05589-3
https://cris.maastrichtuniversity.nl/en/publications/649ba975-66d8-454e-9ae4-f6faf29eec11
https://doi.org/10.1007/s10549-020-05589-3
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103007
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103007
https://link.springer.com/content/pdf/10.1007/s10549-020-05589-3.pdf
https://research.utwente.nl/en/publications/de-escalation-of-axillary-surgery-in-breast-cancer-patients-treat
https://cris.maastrichtuniversity.nl/en/publications/de-escalation-of-axillary-surgery-in-breast-cancer-patients-treat
https://utwente-staging.elsevierpure.com/en/publications/de-escalation-of-axillary-surgery-in-breast-cancer-patients-treat
https://dspace.library.uu.nl/handle/1874/441465
https://hdl.handle.net/2066/225936
https://repository.ubn.ru.nl//bitstream/handle/2066/225936/225936.pdf

Sentinel node total tumour load as a predictive factor for non-sentinel node status in early breast cancer patients – The porttle study

Autoren: Fougo, JL Amendoeira, I Brito, MJ et al.

Weitere Verfasser: Fougo, JL Amendoeira, I Brito, MJ et al.

Quelle: Surgical Oncology. 32:108-114

Schlagwörter: Breast Neoplasms / surgery, Adult, Receptor, ErbB-2, Sentinel Lymph Node Biopsy, Breast Neoplasms, Receptor, ErbB-2 / metabolism, Breast Neoplasms / metabolism, Carcinoma, Lobular / surgery, Young Adult, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Carcinoma, Lobular / secondary, OSNA, Humans, Lymph Nodes / surgery, Carcinoma, Lobular / metabolism, Carcinoma, Ductal, Breast / surgery, Aged, Retrospective Studies, Carcinoma, Ductal, Breast / metabolism, Aged, 80 and over, Lymph Nodes / pathology, Carcinoma, Ductal, Breast, Non-sentinel node, Breast Neoplasms / pathology, Middle Aged, HCC CIR, Prognosis, Receptors, Estrogen / metabolism, 3. Good health, Carcinoma, Lobular, Receptors, Progesterone / metabolism, Sentinel node, Receptors, Estrogen, Lymphatic Metastasis, Carcinoma, Ductal, Breast / secondary, Lymph Nodes / metabolism, Female, Lymph Nodes, Prediction, Receptors, Progesterone, Follow-Up Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/31987574
https://pubmed.ncbi.nlm.nih.gov/31987574/
https://www.sciencedirect.com/science/article/pii/S0960740419304736
https://www.ncbi.nlm.nih.gov/pubmed/31987574
https://europepmc.org/article/MED/31987574
https://hdl.handle.net/10216/143346
http://hdl.handle.net/10400.17/4725

Differential Expression of Sex-Steroid Receptors in the Choroid Aligns With Central Serous Chorioretinopathy Sex Prevalence Across Different Ages

Autoren: Galuh, S. Meijer, O.C. Brinks, J. et al.

Quelle: Invest Ophthalmol Vis Sci
Investigative ophthalmology & visual science, vol. 65, no. 8, pp. 5

Schlagwörter: Male, Adult, 0301 basic medicine, immunostaining, Choroid, steroid receptors, Humans, Female, Choroid/metabolism, Choroid/pathology, Middle Aged, Central Serous Chorioretinopathy/metabolism, Central Serous Chorioretinopathy/epidemiology, Central Serous Chorioretinopathy/diagnosis, Receptors, Progesterone/metabolism, Receptors, Androgen/metabolism, Aged, Sex Factors, Prevalence, Estrogen Receptor alpha/metabolism, Estrogen Receptor alpha, central serous chorioretinopathy (CSC), Retina, 03 medical and health sciences, 0302 clinical medicine, Central Serous Chorioretinopathy, Receptors, Androgen, sex prevalence, sex, Receptors, Progesterone, choroid

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38958971
https://hdl.handle.net/1887/4239168
https://serval.unil.ch/resource/serval:BIB_700DA7CFC0A6.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_700DA7CFC0A6
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_700DA7CFC0A61

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor

Autoren: Valentina Scabia Ayyakkannu Ayyanan Fabio De Martino et al.

Weitere Verfasser: Valentina Scabia Ayyakkannu Ayyanan Fabio De Martino et al.

Quelle: Nat Commun
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Nature communications, vol. 13, no. 1, pp. 3127
Nature Communications

Schlagwörter: 0301 basic medicine, 0303 health sciences, Animals, Breast Neoplasms/metabolism, Estradiol/pharmacology, Estradiol/therapeutic use, Female, Humans, Mice, Progesterone/pharmacology, Receptors, Estrogen/genetics, Receptors, Estrogen/metabolism, Receptors, Progesterone/genetics, Receptors, Progesterone/metabolism, Estradiol, Science, Breast Neoplasms, Estrogen, Article, 3. Good health, 03 medical and health sciences, Receptors, Estrogen, Receptors, Receptors, Progesterone, Progesterone

Dateibeschreibung: application/pdf; Electronic

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35668111
https://doaj.org/article/e90383a7e88449f6abdfb06422e18297
https://serval.unil.ch/resource/serval:BIB_BED35CC8098E.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_BED35CC8098E9
https://serval.unil.ch/notice/serval:BIB_BED35CC8098E

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma

Autoren: Robert L Hollis Tzyvia Rye Melanie Mackean et al.

Quelle: Gynecol Oncol
Hollis, R, Stanley, B, Iida, Y, Thomson, J, Churchman, M, Rye, T, Mackean, M J, Nussey, F, Gourley, C & Herrington, C S 2019, ' Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma ', Gynecologic Oncology, vol. 155, no. 2, pp. 318-323 . https://doi.org/10.1016/j.ygyno.2019.09.001, https://doi.org/10.1016/j.ygyno.2019.09.001

Schlagwörter: Ovarian Neoplasms, 2. Zero hunger, Receptors, Progesterone/metabolism, Estrogen Receptor alpha, Receptors, Androgen/metabolism, Middle Aged, Ovarian Neoplasms/metabolism, Article, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Receptors, Androgen, Estrogen Receptor alpha/metabolism, Humans, Female, Receptors, Progesterone, Carcinoma, Endometrioid, Carcinoma, Endometrioid/metabolism, Retrospective Studies

Dateibeschreibung: application/pdf

Zugangs-URL: http://www.gynecologiconcology-online.net/article/S0090825819314878/pdf
https://pubmed.ncbi.nlm.nih.gov/31495455
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854467
https://www.gynecologiconcology-online.net/article/S0090825819314878/pdf
https://europepmc.org/article/MED/31495455
https://pubmed.ncbi.nlm.nih.gov/31495455/
https://www.gynecologiconcology-online.net/article/S0090-8258(19)31487-8/fulltext
https://www.research.ed.ac.uk/portal/en/publications/hormone-receptor-expression-patterns-define-clinically-meaningful-subgroups-of-endometrioid-ovarian-carcinoma(92404950-521e-468f-b516-011a381222b5).html
https://hdl.handle.net/20.500.11820/92404950-521e-468f-b516-011a381222b5
https://www.pure.ed.ac.uk/ws/files/119443242/1_s2.0_S0090825819314878_main.pdf